Latest news with #Lupin
Time of India
2 days ago
- Business
- Time of India
The Storytelling CIO and the Invisible Engine of AI
At the 7th edition of the ETCIO Annual Conclave, an exclusive leadership summit that brought together India's foremost technology decision-makers, a deceptively simple game of 'Simon Says' opened the afternoon session, offering an unexpected yet powerful cue about attention, perception, and the evolving role of the speaker, Ameen Haque, founder of Storywallahs, stood before a crowd of India's top technology executives. But this wasn't just icebreaking. 'Over a game of simple 'Simon Says',' Haque later explained, 'it was thought-provoking for CIOs, moving you to a place of alertness.' It was a miniature neuroscience experiment: Proof that the brain responds more to visual stimuli than verbal ones. This insight, Haque iterates, holds the key to modern tech leadership. 'We forget facts,' he said, 'but the human brain remembers stories.' That's the paradox CIOs are navigating now. It is to narrate ideas at the intersection of tech and business clearly and quickly to stakeholders who may not understand the language of IT. 'How does one tell a story in the business context,' Haque asked aloud, 'tell it fast and simplify for the non-IT folks?' CIOs Confront the Real Test of AI The question is timely. Across India's boardrooms, digital transformation is in full tilt. Generative AI has emerged not merely as a tool but as a turning point—what Rakesh Bhardwaj, Global CIO at Lupin, calls 'a once-in-a-lifetime opportunity.' Bhardwaj says, 'The bold experiments everyone is doing are paying off. GenAI has come as a hope where we can pole vault. Now we are in the game of translating volatility to opportunity. AI-led autonomy to human centricity.' Yet while India's adoption of AI technologies has outpaced global averages, the real question is not just about uptake—but impact. 'Who's really extracting the value?' Bhardwaj's rhetorical question remains. Ashok Jade, Global CIO of Kirloskar Brothers, knows this challenge all too well. Working within the constraints of a legacy manufacturing enterprise, he sees AI as more than an efficiency engine. 'What if AI could open a new line of business?' he asked. Imagine a future where an AI agent helps a customer select an industrial pump online, surpassing today's three-tiered architecture. 'Moving ahead, can a pump be sold as a service?' he posed. 'Can a digital factory be taken to the customer, consequently?' That tension—between operational safety and technological speed—finds vivid expression in the mobility sector. Manikandan Thangarathnam of Uber India explains, 'Today, Uber operates in 70 countries, drivers uploading vehicle documents—how quickly can we look at allowing them to drive?' But in mobility, haste comes at a price. 'The margin of error is too low; We cannot let a customer drive unsafely,' he said. The key he believes is, 'Understand the scale, depth, and complexity before applying the tech for the problem.' But innovation at Uber hasn't slowed. 'This is the era of transformation in mobility,' Thangarathnam said. 'We can solve traffic in India by more people in lesser vehicles. Lower cost, higher predictability—that's what customers want in shared mobility. So even if it takes four years to solve the problem, it remains evergreen.' If the optimism sounds radical, so does the provocation. Hitesh Sachdev, Head of Innovation & Startups at ICICI Bank, half-jokingly asked, 'Will AI be the CEO of the company?' In some ways, that future doesn't feel entirely far-fetched. The workforce, meanwhile, is undergoing its own metamorphosis. In a rapid-fire round, executives offered one-word answers to a daunting question: How are you rethinking talent in the era of AI? 'Upskilling,' 'Business-first,' and, to applause, 'The person knowing AI will take your job, not AI itself.' Despite concerns of automation replacing roles—over 300,000 jobs and counting—there is also a 2.8% productivity uptick. That trade-off defines the moment. The Invisible Engine: Making AI Work Across Business Some of the biggest wins, however, come from redefining how organizations make decisions and execute at scale. Kenny Kesar, Global CIO at Wipro, explains, 'We asked: How do we move from scattered innovation to systemic?' The $11 billion company transitioned from viewing AI as an external pilot to an internal imperative. 'We moved from AI-as-a-thing to AI-in-everything,' he said. Wipro's AI-infused go-to-market tools now include deal intelligence systems and proposal copilots, built on a platform called AI Fabric. 'True transformation happens when AI is the invisible engine.' The metaphor sticks. 'AI is a convex lens in the hands of visionary leadership,' Kesar added, explaining how Wipro deployed 70 enterprise-wide AI use cases and instituted MLOps to scale further. The next frontier? Equipping 235,000 employees with AI skills. In a room full of CIOs, the storytelling wasn't just about technology. It was about re-imagining what leadership looks like in the age of algorithms. And, as Haque suggested, the most powerful shift isn't technical at all. 'Some of the best tech leaders,' he said simply, 'are good storytellers.' The rest, after all, is just data.
Business Standard
4 days ago
- Business
- Business Standard
Lupin grants 7,337 stock options
Lupin has granted 7,337 stock options on 27 May 2025. Please note that upon vesting, one stock option entitles the grantee to subscribe to one equity share of the Company of Rs 2.00 each. The vesting schedule of stock options will be 25%:25%:25%:25% over four years upon completion of one year from the date of by Capital Market - Live News
Yahoo
4 days ago
- Business
- Yahoo
Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology
MUMBAI, India, NAPLES, Fla. and CHICAGO, May 27, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025. The presentation titled 'A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors,' will be featured in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session. It can be viewed at Poster Board #422 on June 2, 2025, from 1.30 pm to 4.30 pm (CDT). Key findings from the study include: LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, with desirable PK/PD profile and no impact of food on the pharmacokinetics. The maximum tolerated dose, recommended phase 2 dose was determined based on safety, efficacy, PK/PD data, aligning with preclinical findings and the known safety profile of PRMT5 inhibitors. "We are delighted to share the initial results from Phase I study of our PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. We are committed to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to-treat cancers," said Vinita Gupta, CEO, Lupin. Current data from Lupin indicates that LNP7457 is unique within its field and appears to be safe and well-tolerated as a SAM-competitive PRMT5 inhibitor. Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India and explore its potential for treatment of cancers with significant unmet medical needs. Details of the Presentation: Date and time: June 2, 2025, 1:30 pm – 4:30 pm (CDT) Location: Hall A - Posters and Exhibits | McCormick Place, Chicago, IL Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Sub Track: Small Molecules Clinical Trial Registration Number: CTRI/2023/07/054753 Doi: 10.1200/JCO.2025.43.16_suppl.3107 Abstract Number: 3107 Poster Board Number: 422 Abstract link: About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn Logo: View original content: SOURCE Lupin Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
5 days ago
- Business
- Time of India
Novartis offers payment plan for high-cost heart medicine
Mumbai: In a first-of-its-kind pricing strategy in the pharmaceutical industry, Swiss drug major Novartis has introduced a financing scheme for its cholesterol lowering drug brand Sybrava (inclisiran) in India, as the company looks to expand the adoption of the new generation heart drug that has so far been restricted due to its high pricing. Novartis has tied up with Indian payment technology company Pine Labs to offer a monthly instalment scheme for the twice-a-year treatment of the injectable drug used to reduce levels of low-density lipoprotein cholesterol (LDL-C), commonly called bad cholesterol. "We have recently launched a zero-interest EMI scheme with Pine Labs so that this treatment can be accessible to more patients," Amitabh Dube, country president & MD, Novartis India, said in an exclusive interview with ET. Each instalment is priced at Rs 15,000-16,000. "The first is a loading dose and the second dose is after 90 days, and then after 180 days. It will be a rolling cycle," said Dube. As per cardiologists, Novartis has come up with a one-on-one scheme where the second injection will be free on purchase of the first dose. However, a patient has to pay full value of the first dosage through equated monthly instalment. The drug was priced at Rs 1.2 lakh per injection when it was launched in January 2024. In the US, sold under brand Leqvio, it is priced at $3,373.4 per dose (about Rs 2.9 lakh). More than 3,000 patients have currently been put on the drug in India. To expand the reach for inclisiran, Novartis has also entered into marketing tie-ups with Mankind Pharma , JB Pharma and Lupin . Mankind, which sells inclisiran under brand Crenzlo, is also evaluating possibilities in terms of patient assistance programmes that can make the drug more affordable to the eligible patients in India, said Atish Majumdar, senior president-sales and marketing. Lupin has launched the drug under Tilpazan, while JB Pharma's brand is Izirize. Lupin and JB Pharma did not respond to ET's query until press time on Monday. In the one year since April 2024, inclisiran recorded sales of Rs 7.7 crore among all three partners, according to data from PharmaTrac. Inclisiran is not a replacement for statins, the most commonly used class of medications to lower cholesterol, but can be recommended as a line of treatment when statins do not work or if a person is statin intolerant. However, top cardiologists are divided over the widespread prescribing of the drug. Some opine it is another addition to their armament of treatment. "It is a very important drug that has come into the market. It has the potential to be a very big game changer for blockages," said Dr Nihar Mehta, associate director, Department of Structural Heart Diseases, Jaslok Hospital & Research Centre. However, others said its usage will be for a limited number of patients. Dr Ganesh Kumar AV, director of cardiology at LH Hiranandani Hospital Powai in Mumbai, said: "The medicine is good but it is being overused. With the right usage there are not many patients who need it. My usage of inclisiran has not been much over the last one year; maybe less than 10 out of the about 2,000 patients with coronary artery diseases I treated".
The Hindu
5 days ago
- Business
- The Hindu
Lupin, SteinCares ink pact to roll out biosimilar for eye disease in Latin America
Drugmaker Lupin has entered into a licence and supply agreement with SteinCares for commercialisation of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. SteinCares, which is specialty healthcare company in Latin America, will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same, under the agreement, it said on Monday. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy and Myopic Choroidal Neovascularization, Lupin said. 'Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Cyrus Karkaria, president – Biotechnology, Lupin, said in a release. Chief Strategy Officer at SteinCares Sebastian Katz said the company has consistently been the first to market products from highly regulated markets across several countries in the region. The partnership with Lupin strengthens its portfolio and reinforces SteinCares' position as a biosimilar powerhouse in Latin America.
